Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKesson
Express Scripts
Harvard Business School
AstraZeneca

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,178,563

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,178,563 protect, and when does it expire?

Patent 8,178,563 protects ODOMZO and is included in one NDA.

This patent has sixty-four patent family members in forty-five countries.

Summary for Patent: 8,178,563
Title:Compounds and compositions as hedgehog pathway modulators
Abstract: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
Inventor(s): Gao; Wenqi (San Diego, CA), Jiang; Jiqing (San Diego, CA), Wan; Yongqin (Irvine, CA), Cheng; Dai (San Diego, CA), Han; Dong (San Diego, CA), Wu; Xu (San Diego, CA), Pan; Shifeng (San Diego, CA)
Assignee: IRM LLC (Hamilton, BM)
Application Number:12/299,290
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 8,178,563

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharma Global ODOMZO sonidegib phosphate CAPSULE;ORAL 205266-001 Jul 24, 2015 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF BASAL CELL CARCINOMA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,178,563

PCT Information
PCT FiledMay 04, 2007PCT Application Number:PCT/US2007/068292
PCT Publication Date:November 15, 2007PCT Publication Number: WO2007/131201

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Boehringer Ingelheim
Express Scripts
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.